ArticleJournal of substance abuse treatment2023
Not in my treatment center: Leadership's perception of barriers to MOUD adoption.
Article in Journal of substance abuse treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- "They should be like penicillin": barriers to the integration of medications for opioid use disorder in specialty treatment programs.Addiction science & clinical practice · 2025Article
- Opioid and alcohol use disorder medication availability in outpatient care: national estimates & potential policy levers.Health affairs scholar · 2025Article
- Perceived organizational support for the treatment of opioid use disorder and its association with primary care provider treatment willingness and medication prescribing.Journal of substance use and addiction treatment · 2025Article
- Real-world access to buprenorphine treatment in Philadelphia: A secret shopper study.Drug and alcohol dependence · 2025Article
- Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder.Addiction science & clinical practice · 2025Article
- Client and program-level factors associated with planned use of medications for opioid use disorder in specialty substance use treatment programs: Evidence from linked administrative data and survey data.Journal of substance use and addiction treatment · 2025Article
- Limited acceptance of buprenorphine in recovery residences in South Florida: A secret shopper survey.Journal of substance use and addiction treatment · 2025Article
- Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.Journal of substance use and addiction treatment · 2024Article
- Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder.Research square · 2024Article
- Article
- Differences in buprenorphine prescribing readiness among primary care professionals with and without X-waiver training in the US.Harm reduction journal · 2023Article
- Medication Approaches for Patients With Opioid Use Disorders: Differences Between Primary Care Clinics and Specialty Addiction Treatment Programs.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionDespite their well-established effectiveness, medications for opioid use disorder (MOUD) are widely underutilized across the United States. In the context of a large publicly funded behavioral health system, we examined the relationship between a range of implementation barriers and a substance use disorder treatment agency's level of adoption of MOUD.
methodsWe surveyed leadership of publicly funded substance use disorder treatment centers in Philadelphia about the significance of barriers to implementing MOUD related to their workforce, organization, funding, regulations, and beliefs about MOUD's efficacy and safety. We queried leaders on the percentage of their patients with opioid use disorder who receive MOUD and examined associations between implementation barriers and MOUD adoption.
resultsRatings of regulatory, organizational, or funding barriers of respondents who led high MOUD adopting agencies (N = 20) were indistinguishable from those who led agencies that were low adopting of MOUD (N = 23). In contrast, agency leaders who denied MOUD-belief or workforce barriers were significantly more likely to lead high-MOUD-adopting organizations.
conclusionsThese findings suggest that leadership beliefs about MOUD may be a key factor of the organizational decision to adopt and should be a target of implementation efforts to increase direct provision of these medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.